Prev Arrow Stocks

Waters Corporation ($WAT) Stock Forecast: Up 12.1% Today

Morpher AI identified a bullish signal. The stock price may continue to rise based on the momentum of the good news.

What is Waters Corporation?

Waters Corporation (NYSE: WAT) operates in the life sciences sector, focusing on analytical technologies essential in various industries such as pharmaceuticals, biotechnology, and environmental testing.

Why is Waters Corporation going up?

WAT stock is up 12.1% on May 5, 2026 17:36

  • Waters Corporation (WAT) witnessed a significant upward trend in its stock performance today.
  • The company exceeded market expectations in both adjusted EPS and revenue during the first quarter.
  • The strong results were linked to the successful incorporation of its newly acquired Biosciences and Diagnostic Solutions divisions, driving organic growth and enhancing the overall positive sentiment.
  • The company's decision to increase its projected figures for adjusted EPS and total revenue for the full year 2026 further boosted investor confidence, indicating sustained growth and profitability ahead.

WAT Price Chart

WAT Technical Analysis

WAT News

Aptiv Releases Q1 2026 Financial Results

Aptiv PLC reported first-quarter 2026 results that exceeded Wall Street expectations, with adjusted earnings of $1.71 per share against an estimated $1.60. The automotive technology supplier generated $5.09 billion in revenue, a 5.0% increase year-over-year, driven primarily by strong performance in its Signal and Power Solutions segment. The company also provided adjusted earnings guidance for the full fiscal year 2026, ranging from $5.70 to $6.10 per share.

https://news.alphastreet.com/aptiv-releases-q1-2026-financial-results/

0 News Article Image Aptiv Releases Q1 2026 Financial Results

Waters Corporation stock rises 5% on strong earnings beat By Investing.com

Waters Corporation (NYSE:WAT) stock rose 5% in pre-market trading after the company reported first-quarter results that surpassed analyst expectations. The life sciences company posted adjusted EPS of $2.70 on revenue of $1.27 billion, exceeding estimates, partially due to the strong performance of its recently acquired Biosciences and Diagnostic Solutions businesses. Waters also raised its full-year 2026 guidance, expecting adjusted EPS of $14.40 to $14.60 and total revenue of $6.405 billion to $6.455 billion.

https://ca.investing.com/news/earnings/waters-corporation-stock-rises-5-on-strong-earnings-beat-93CH-4608471

1 Missing News Article Image Waters Corporation stock rises 5% on strong earnings beat By Investing.com

Waters Corporation stock rises 5% on strong earnings beat By Investing.com

Waters Corporation (NYSE:WAT) saw its shares climb over 5% in pre-market trading after reporting first-quarter results that surpassed analyst expectations. The life sciences company posted adjusted EPS of $2.70 and revenue of $1.27 billion, exceeding estimates, driven by strong organic growth and contributions from its recent acquisition of Biosciences and Diagnostic Solutions. Waters also raised its full-year 2026 guidance for adjusted EPS and total revenue, signaling continued confidence in its performance.

https://za.investing.com/news/earnings/waters-corporation-stock-rises-5-on-strong-earnings-beat-93CH-4252048

2 Missing News Article Image Waters Corporation stock rises 5% on strong earnings beat By Investing.com

Waters reports Q1 2026: $1.267B revenue, adjusted EPS $2.70, raises FY26 guidance

Waters (WAT) reported strong financial results for Q1 2026, with net revenue of $1.267 billion and adjusted diluted EPS of $2.70, representing a 20% year-over-year increase. The company also raised its full-year 2026 adjusted EPS guidance to $14.40–$14.60 and increased organic constant-currency revenue growth guidance to 6.5%–8.0%, driven by successful integration of its Biosciences and Diagnostic Solutions acquisition and broad growth across regions.

https://www.tradingview.com/news/tradingview:cf21ccc0b3bce:0-waters-reports-q1-2026-1-267b-revenue-adjusted-eps-2-70-raises-fy26-guidance/

3 News Article Image Waters reports Q1 2026: $1.267B revenue, adjusted EPS $2.70, raises FY26 guidance

Waters (NYSE: WAT) Q1 revenue surges after BD biosciences acquisition

Waters Corporation reported a significant surge in Q1 2026 revenue to $1.267 billion, up 91% year-over-year, primarily driven by the acquisition of Biosciences and Diagnostic Solutions businesses from Becton, Dickinson and Company. Despite a GAAP diluted loss per share due to acquisition-related accounting charges, adjusted diluted EPS grew 20% to $2.70. The company also raised its full-year 2026 guidance for organic revenue growth and adjusted EPS, reflecting strong performance and integration momentum.

https://www.stocktitan.net/sec-filings/WAT/8-k-waters-corp-de-reports-material-event-3b3b327dc5e5.html

4 News Article Image Waters (NYSE: WAT) Q1 revenue surges after BD biosciences acquisition

Waters Corporation Price History

13.01.2026 - WAT Stock was up 5.3%

  • Waters Corporation (WAT) experienced a strong bullish movement today, potentially driven by the following factors:
  • Despite a recent 19% decline in the stock price, analysts are optimistic about a turnaround, with the stock being in oversold territory and showing signs of rebound potential.
  • The company reported robust Q4 and full-year 2025 results, with strong sales and earnings, as well as providing optimistic guidance for 2026.
  • Waters' recent acquisition of BD Biosciences and Diagnostic Solutions is expected to contribute significantly to revenue growth and synergies, boosting investor confidence in the company's future prospects.
  • The positive sentiment surrounding Waters Corporation contrasts with the news about another company, which has been undergoing changes such as the sale of its Life Sciences business and facing mixed analyst reactions, potentially diverting investor attention towards WAT's more promising outlook.

30.03.2026 - WAT Stock was up 5.4%

  • Despite its recent underperformance against competitors, Waters Corp. stock displayed a bullish movement.
  • Investor interest in Waters Corp. might have been ignited by ongoing merger activities within the industry.
  • The stock's trading below its 52-week high potentially attracted bargain hunters seeking upward potential.
  • The favorable market sentiment towards the sector likely contributed to the bullish movement in Waters Corp. stock.

30.03.2026 - WAT Stock was up 5.9%

  • Vanguard Capital Management's significant ownership stake in Waters Corp likely boosted investor confidence, driving increased buying activity and pushing the stock price up.
  • Previous underperformance of Waters Corp's stock compared to competitors may have presented an attractive buying opportunity, contributing to today's bullish trend.
  • A shareholder alert about investigations into mergers at other companies could have shifted focus away from Waters Corp, enabling independent stock rallying.
  • Market conditions and investor sentiment likely played a part in driving Waters Corp's stock upward, despite broader market downturns.

08.03.2026 - WAT Stock was up 5.9%

  • The bullish movement in Waters Corp's stock (WAT) can be attributed to the following factors:
  • Approval of Waters' at-home cervical cancer screening kit is a significant milestone, enhancing the company's product portfolio and potentially increasing its market share in the healthcare sector.
  • The approval is expected to drive revenue growth as the kit allows for convenient at-home sample collection, catering to the un/under-screened population, thereby addressing a critical healthcare need.
  • Waters Corp's strong market position in essential industries like drug discovery and environmental testing, coupled with its diversified portfolio and recurring revenue model, provides investors with confidence in its long-term growth prospects.
  • Despite facing risks such as supply chain disruptions, the company's strategic focus on innovation and its role in critical industries position it favorably for sustained success in the market.

25.02.2026 - WAT Stock was down 0.7%

  • Waters Corporation (WAT) experienced a bearish movement today, possibly influenced by the company's recent issuance of $3.5 billion in senior notes to refinance a term loan.
  • The market may have reacted negatively to the significant debt increase, which could raise concerns about Waters' financial leverage and future cash flows.
  • Despite the bearish movement, investors should keep an eye on Agilent Technologies Inc. (A) as its innovative chromatography solutions launch has boosted investor confidence and positioned the company for sustained revenue growth in the life sciences market.
  • The sale of Alphabet Inc. (GOOGL) shares by Representative Thomas H. Kean, Jr. may have also contributed to market jitters, reflecting potential profit-taking activities among institutional investors.

18.01.2026 - WAT Stock was up 5.0%

  • Waters Corporation's bullish movement can be attributed to the launch of their new 1 mm I.D. liquid chromatography (LC) columns with MaxPeak Premier Technology. This innovation promises higher sensitivity, reduced sample usage by 75%, and decreased solvent consumption by up to four times compared to traditional columns, catering to high-throughput bioseparations and pharmaceutical applications.
  • The positive market sentiment towards Waters Corporation could also be influenced by the overall growth projections of the Gas Chromatography Systems Market, which is expected to reach US$7.20 billion by 2032. This indicates a rising demand for advanced analytical instrumentation, benefiting companies like Waters Corporation.
  • The emphasis on technological advancements by key players in the gas chromatography market, such as Thermo Fisher Scientific and Agilent Technologies, further highlights the potential for growth and innovation in the sector. Waters Corporation's introduction of cutting-edge technology aligns with this trend, likely contributing to the bullish movement of their stock.
  • Waters Corporation's focus on enhancing sensitivity, sample recovery, and data quality through their new LC columns positions them well to capitalize on the increasing demand for analytical solutions in various industries, potentially driving further positive momentum in their stock performance.

12.01.2026 - WAT Stock was down 5.3%

  • Waters Corporation (WAT) experienced a bearish movement following a price target downgrade by an analyst from Wells Fargo.
  • The downgrade may be linked to the upcoming merger with BD's life science and diagnostics business, leading to investor uncertainty about the combined entity's future prospects.
  • Despite the downgrade, analysts from Guggenheim and HSBC have issued positive ratings and higher price targets, indicating varying opinions on the merger's potential success.
  • Investor behavior suggests a keen interest in monitoring the merger's developments and its possible impact on Waters Corporation's growth in the competitive life sciences industry.

12.01.2026 - WAT Stock was down 5.5%

  • Waters Corporation's stock slipped despite beating Q4 expectations, indicating investor disappointment in the company's outlook. This could have contributed to the bearish movement.
  • The news of Becton, Dickinson and Company (BDX) raising its price target and reporting strong Q1 results might have shifted investor focus towards BDX, leading to a relative sell-off of WAT shares.
  • The merger of BD's Biosciences & Diagnostics business with Waters Corporation could have caused uncertainty among investors regarding the future prospects of Waters Corporation, impacting its stock performance negatively.
  • Despite Waters Corporation's recent challenges, focusing on strategic growth opportunities and improving outlook could help regain investor confidence and stabilize the stock price in the future.

05.04.2026 - WAT Stock was up 12.1%

  • Waters Corporation (WAT) witnessed a significant upward trend in its stock performance today.
  • The company exceeded market expectations in both adjusted EPS and revenue during the first quarter.
  • The strong results were linked to the successful incorporation of its newly acquired Biosciences and Diagnostic Solutions divisions, driving organic growth and enhancing the overall positive sentiment.
  • The company's decision to increase its projected figures for adjusted EPS and total revenue for the full year 2026 further boosted investor confidence, indicating sustained growth and profitability ahead.

23.03.2026 - WAT Stock was down 8.8%

  • The bearish movement in Waters Corporation's stock today could be attributed to the spin-off of Becton Dickinson's biosciences and diagnostic solutions business, which was combined with Waters Corporation. This significant transaction valued at $18.8 billion might have raised concerns among investors about the potential impact on Waters Corporation's future performance and market positioning.
  • Additionally, advancements in the healthcare industry, such as GE HealthCare's development of a manganese-based MRI contrast agent as an alternative to gadolinium-based agents, could have shifted investor focus towards companies directly involved in healthcare innovations, leading to a temporary dip in Waters Corporation's stock.
  • The global Cloud ELN Service market's projected growth and emphasis on digital transformation in research, particularly with companies like Thermo Fisher Scientific and Agilent Technologies driving this evolution, might have diverted investor attention away from traditional laboratory equipment providers like Waters Corporation, contributing to the bearish movement in the stock.
  • Overall, the market movement in Waters Corporation today could be a result of shifting investor sentiments towards healthcare innovation and digital laboratory transformation, impacting the company's stock performance in the short term.

27.02.2026 - WAT Stock was down 5.5%

  • Waters Corp stock faced a bearish movement possibly due to growth challenges, despite favorable sector tailwinds.
  • The company's mixed recent performance and analyst ratings leaning towards a "Moderate Buy" might have contributed to investor uncertainty and selling pressure.
  • The bearish trend could also be influenced by the overall slowdown in the life sciences sector, indicating broader industry challenges impacting companies like Waters Corp.
  • Investors may be cautious about the company's ability to navigate these growth challenges and maintain its competitive position in the market, leading to the bearish movement in the stock.

05.04.2026 - WAT Stock was up 11.4%

  • Waters Corporation (WAT) witnessed a strong bullish movement today, with its stock increasing over 5% in pre-market trading.
  • The surge in WAT's stock price is attributed to the company's impressive first-quarter 2026 financial results, surpassing analyst expectations.
  • Contributing factors to this bullish trend include the company's robust revenue of $1.27 billion, adjusted EPS of $2.70, and increased full-year 2026 guidance for both adjusted EPS and total revenue.
  • The successful integration of its recent acquisition of Biosciences and Diagnostic Solutions, combined with strong organic growth, significantly influenced Waters Corporation's positive performance and investor confidence.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.